| Identification | Back Directory | [Name]
2H-1-Benzopyran-6-carbonitrile, 4-[(4-chlorophenyl)(1H-iMidazol-2-ylMethyl)aMino]-3,4-dihydro-3-hydroxy-2,2-diMethyl-, Monohydrochloride, (3R,4S)- (9CI) | [CAS]
166095-95-0 | [Synonyms]
BMS-191095 hydrochloride >=98% (HPLC)
(3R,4S)-4-[4-chloro-N-(1H-imidazol-2-ylmethyl)anilino]-3-hydroxy-2,2-dimethyl-3,4-dihydrochromene-6-carbonitrile:hydrochloride
2H-1-Benzopyran-6-carbonitrile, 4-[(4-chlorophenyl)(1H-iMidazol-2-ylMethyl)aMino]-3,4-dihydro-3-hydroxy-2,2-diMethyl-, Monohydrochloride, (3R,4S)- (9CI) | [Molecular Formula]
C22H22Cl2N4O2 | [MDL Number]
MFCD00953840 | [MOL File]
166095-95-0.mol | [Molecular Weight]
445.342 |
| Hazard Information | Back Directory | [Uses]
BMS-191095 hydrochloride is a mitochondrial KATP channel opener. BMS-191095 hydrochloride can protect the myocardium without causing vasodilation or affecting electrophysiology, by prolonging the contraction time during ischemia, improving contractile function after reperfusion, and reducing lactate dehydrogenase (LDHM) release, thereby exerting its cardioprotective effects[1]. | [Biological Activity]
BMS-191095 is a potent and selective mitochondrial ATP-sensitive K1 channel (KATP) channel opener devoid of peripheral vasodilating activity. BMS-191095 improves postischemic recovery of function and reduced lactate dehydrogenase release in the isolated r at hearts. | [References]
[1] Grover GJ, et al. Pharmacologic profile of the selective mitochondrial-K(ATP) opener BMS-191095 for treatment of acute myocardial ischemia. Cardiovasc Drug Rev. 2002 Summer;20(2):121-36. DOI:10.1111/j.1527-3466.2002.tb00187.x |
|
| Company Name: |
Energy Chemical
|
| Telephone: |
400-0056266 |
| Website: |
www.energy-chemical.com |
| Company Name: |
TargetMol
|
| Telephone: |
400-821-0310 15002144251 |
| Website: |
www.targetmol.cn/ |
|